Semnur Registers 203.7M Shares for Resale Post-Merger, Warrants to Boost Capital

TL;DR

**Semnur's S-1 signals massive potential dilution from selling stockholders, making SMNR a risky bet despite warrant exercise proceeds.**

AI Summary

Semnur Pharmaceuticals, Inc. (SMNRW) filed an S-1 on October 21, 2025, primarily to register the issuance of up to 8,760,000 shares of common stock upon the exercise of warrants and the resale of up to 203,737,349 shares of common stock by various selling stockholders. The company will not receive proceeds from the resale of these shares, but will receive proceeds from the exercise of the warrants. Key selling stockholders include Scilex Holding Company with up to 188,554,849 shares, Biconomy PTE.LTD with up to 12,500,000 shares, and various Denali Capital Acquisition Corp. sponsors holding 2,072,500 shares. The filing follows the consummation of a business combination on September 22, 2025, where Denali Capital Acquisition Corp. merged with Legacy Semnur and changed its name to Semnur Pharmaceuticals, Inc. The company's common stock and public warrants trade on the Pink Limited Market under symbols 'SMNR' and 'SMNRW', with last reported sales prices of $9.00 per share and $0.20 per warrant, respectively, as of October 17, 2025. Semnur is an 'emerging growth company' and has elected to comply with reduced reporting requirements.

Why It Matters

This S-1 filing is crucial for investors as it outlines the significant potential for dilution from the resale of over 203 million shares by selling stockholders, including Scilex Holding Company and Biconomy PTE.LTD. While Semnur will receive cash from warrant exercises, the lack of proceeds from the massive share resale means no direct capital infusion for operations from this specific offering. The competitive landscape in pharmaceuticals, coupled with the company's 'emerging growth company' status and trading on the Pink Limited Market, suggests higher risk and potential volatility for existing and prospective shareholders. Employees and customers may see this as a necessary step for liquidity, but the sheer volume of shares could pressure the stock price.

Risk Assessment

Risk Level: high — The risk level is high due to the registration of up to 203,737,349 shares for resale by selling stockholders, which represents a substantial portion of the company's potential outstanding shares and could lead to significant dilution and downward pressure on the stock price. Additionally, the company's common stock and public warrants trade on the Pink Limited Market, which typically implies lower liquidity and higher volatility compared to major exchanges. The filing also explicitly states, 'INVESTING IN OUR COMMON STOCK INVOLVES SUBSTANTIAL RISKS.'

Analyst Insight

Investors should exercise extreme caution and thoroughly review the 'Risk Factors' section of the S-1. Given the potential for significant dilution from the 203,737,349 resale shares and the Pink Limited Market listing, consider waiting for more stable trading conditions and clearer operational milestones before investing. Monitor the volume and price action of SMNR and SMNRW closely for signs of selling pressure.

Key Numbers

• 203,737,349 — Shares of Common Stock (Maximum number of shares offered for resale by Selling Stockholders)
• 8,760,000 — Shares of Common Stock (Maximum number of shares issuable upon exercise of Warrants)
• 510,000 — Private Placement Warrants (Number of Private Warrants registered for resale)
• $9.00 — Common Stock Price (Last reported sales price per share on October 17, 2025)
• $0.20 — Public Warrant Price (Last reported sales price per warrant on October 17, 2025)
• 188,554,849 — Scilex Shares (Shares held by Scilex Holding Company for resale)
• 12,500,000 — Biconomy Resale Shares (Shares held by Biconomy PTE.LTD for resale)
• 2,072,500 — Sponsor Shares (Shares held by Denali Capital Global Investments LLC transferees for resale)
• September 22, 2025 — Business Combination Date (Date the merger between Denali Capital Acquisition Corp. and Legacy Semnur was consummated)
• October 21, 2025 — Filing Date (Date the S-1 registration statement was filed)

Key Players & Entities

• Semnur Pharmaceuticals, Inc. (company) — Registrant and post-merger entity
• Denali Capital Acquisition Corp. (company) — Pre-merger SPAC
• Scilex Holding Company (company) — Selling Stockholder of up to 188,554,849 shares
• Biconomy PTE.LTD (company) — Selling Stockholder of up to 12,500,000 shares
• Jaisim Shah (person) — Chief Executive Officer of Semnur Pharmaceuticals, Inc.
• U.S. Securities and Exchange Commission (regulator) — Filing oversight body
• Paul Hastings LLP (company) — Legal counsel for Semnur Pharmaceuticals, Inc.
• VStock Transfer, LLC (company) — Warrant agent
• US Tiger Securities, Inc. (company) — Underwriter of Denali's IPO
• D. Boral Capital, LLC (company) — Underwriter of Denali's IPO

FAQ

Key Financial Figures

• $0.0001 — 0 shares of our common stock, par value $0.0001 per share ("Common Stock"), issuable up
• $9.00 — price per share of our Common Stock was $9.00. On October 17, 2025, the last reported
• $0.20 — per warrant of our Public Warrants was $0.20. We are an "emerging growth company"
• $11.50 — one share of Common Stock at a price of $11.50 per share. " Registration Rights Agre
• $2,000,000 — ponsor in the total principal amount of $2,000,000, which bore interest equivalent to the
• $10.00 — rdinary Shares at a conversion price of $10.00 per ordinary share

Filing Documents

• d63562ds1.htm (S-1) — 4043KB
• d63562dex51.htm (EX-5.1) — 19KB
• d63562dex1014.htm (EX-10.14) — 97KB
• d63562dex231.htm (EX-23.1) — 2KB
• d63562dex232.htm (EX-23.2) — 1KB
• d63562dex233.htm (EX-23.3) — 10KB
• d63562dexfilingfees.htm (EX-FILING FEES) — 25KB
• g63562dsp11.jpg (GRAPHIC) — 11KB
• g63562g00z31.jpg (GRAPHIC) — 116KB
• g63562g1017043336769.jpg (GRAPHIC) — 2KB
• g63562g1018002926517.jpg (GRAPHIC) — 3KB
• g63562g1018002926773.jpg (GRAPHIC) — 5KB
• g63562g79p40.jpg (GRAPHIC) — 11KB
• 0001193125-25-245178.txt ( ) — 13473KB
• smnr-20250630.xsd (EX-101.SCH) — 1479KB
• d63562ds1_htm.xml (XML) — 2137KB
• d63562dexfilingfees_htm.xml (XML) — 9KB

USE OF PROCEEDS

USE OF PROCEEDS 91 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES 92 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION 100

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 116

BUSINESS

BUSINESS 128 EXECUTIVE AND DIRECTOR COMPENSATION 169 DIRECTORS AND EXECUTIVE OFFICERS 177

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 190 SELLING SECURITYHOLDERS 192 PLAN OF DISTRIBUTION 194

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 198 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 210 LEGAL MATTERS 217 EXPERTS 217 TRANSFER AGENT AND REGISTRAR 218 WHERE YOU CAN FIND MORE INFORMATION 218 INDEX TO FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using the "shelf" registration process. Under this shelf registration process, the Selling Securityholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such Selling Securityholders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock issuable upon the exercise of the Warrants. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash. Neither we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholders will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable

View Full Filing

View this S-1 filing on SEC EDGAR